BrainParrot

Economic policy cannot outweigh citizens’ lives: SC on medicine prices

GS2Full notePublished: · Updated:

Source: The Hindu, 28 October 2026

Summary

  • A Bench of Justices Vikram Nath and Sandeep Mehta questioned the Centre over why the National Pharmaceutical Pricing Authority (NPPA) has not capped trade margins on essential medicines despite concerns over excessive mark-ups. It said "economic policy" cannot outweigh citizens' lives.
  • The Bench also asked why the anti-cancer drug margin cap came only after the Court's intervention. It reserved its order and gave parties two weeks to file submissions.

UPSC relevance: GS2/GS3 — Polity: Right to health (Art. 21), Directive Principles, judiciary and executive; Economy: price regulation, essential commodities

Key facts for Prelims

  • NPPA: est. 29 August 1997; functions under the Department of Pharmaceuticals (Ministry of Chemicals and Fertilizers).
  • DPCO, 2013: issued under Section 3, Essential Commodities Act, 1955.
  • Scheduled formulations (First Schedule, from the NLEM) have government-fixed ceiling prices. Non-scheduled formulations are monitored, with a 10% annual increase limit.
  • Ceiling price = average price to retailer of brands with 1% or more market share, plus a 16% retailer margin.
  • Ceiling prices are revised annually on 1 April on the basis of the Wholesale Price Index.
  • Para 19 of DPCO, 2013: extraordinary powers in public interest. This is the basis for the cancer-drug margin cap.
  • DPCO 2013 was issued by the Ministry of Chemicals and Fertilisers on the basis of NPPP 2012 for the NLEM-2011 medicines (NLEM is issued by the Ministry of Health and Family Welfare).
  • Consumers can check revised prices on the Pharma Sahi Daam app and the NPPA website.
  • Art. 21 (right to life, including health) and Art. 47 (State's duty to improve public health) provide the constitutional frame.

Data and details

  • Bench: Justices Vikram Nath and Sandeep Mehta; ASG Aishwarya Bhati appeared for the Centre. Petitioners: advocate Kishan Chand Jain and paediatric surgeon Sanjay Kulshrestha, who want stricter enforcement of the DPCO, 2013 to curb disproportionate margins across the supply chain.
  • Earlier this month NPPA capped trade margins on 137 non-scheduled anti-cancer medicines at 30% of MRP; the revised prices take effect 9 November.
  • The Bench questioned the Centre's inaction ("For so many years, why were you silent?") and warned it not to force "harsh questions". It asked why the cap came only after its intervention.
  • The Bench asked why the 16% retailer margin under the DPCO should not apply to all essential medicines. It also asked for the basis of classifying drugs as scheduled or non-scheduled.
  • Justice Mehta: "How do you decide which medicine is essential and which is not? Why should all medicines not be essential?" He added the NPPA "seems to be totally defunct".
  • Centre's stand (ASG): "complete government control" over essential medicines could hurt the market. The Centre wants investments, can intervene from time to time, and says complete control is not the answer.
  • Hospitals' stand: senior advocate Mukul Rohatgi, for an association of hospitals, said capping margins on essential medicines, including anti-cancer drugs, would make hospital operations financially unviable. The Bench rejected this, saying patients cannot be subjected to "dacoity".
  • Procedure: order reserved; two weeks to file submissions.

Static–dynamic linkage

  • Static concept. Medicines are regulated as "essential commodities". Under the Essential Commodities Act, 1955 the Centre issues the Drugs (Prices Control) Order (DPCO). Only "scheduled" drugs (those on the National List of Essential Medicines-linked First Schedule) get a ceiling price, while "non-scheduled" drugs are monitored.
  • Bridge. The Court's questions go to the design of this two-tier system. Is the scheduled/non-scheduled cut-off a rational test of "essential"? Why should the 16% retailer margin not apply across all essential medicines? When can the extraordinary power in Para 19 be used in public interest? The Centre's reply is the market-versus-control argument: complete control deters investment.
  • Constitutional hook. The Court's remark connects the right to life and health (Art. 21) and the State's duty to raise public health (Art. 47) to price regulation, an economic-policy domain.

Syllabus mapping: GS3 — Economy: Government policies, pricing and regulation, essential commodities. GS2 — Polity/Governance: Health, Fundamental Rights (Art. 21), DPSP (Art. 47), regulatory bodies.

Background primer

National Pharmaceutical Pricing Authority (NPPA)

What it is:
an independent body of experts established on 29 August 1997 as per a Cabinet Committee decision of September 1994 while reviewing drug policy.
Mandate:
fixation and revision of prices of pharmaceutical products, enforcement of the Drugs (Prices Control) Order, and monitoring of prices of controlled and decontrolled drugs.

Drugs (Prices Control) Order, 2013 (DPCO)

What it is:
an Order issued under Section 3 of the Essential Commodities Act, 1955.
Founded:
notified on 15 May 2013 following the National Pharmaceutical Pricing Policy (NPPP) 2012. It replaced the 1995 order.
Why it matters:
availability of essential and life-saving medicines at a reasonable price.

Additional context

  • The 17 October 2026 notification. The NPPA undertook Trade Margin Rationalisation (TMR) of 137 identified non-scheduled anti-cancer drugs in public interest.
    • The measure is expected to cut MRPs by up to 70%, depending on existing price structures.
    • The cap is under Para 19 of the DPCO, 2013.
    • An Expert Committee under the DGHS recommended the 137 drugs.
    • Manufacturers must inform NPPA of revised prices within 7 days of the Gazette notification.
    • State Drug Controllers are to ensure compliance by manufacturers, dealers, retailers and hospitals.
  • Antecedent. This builds on NPPA's 2019 pilot TMR exercise that capped margins on 42 anti-cancer drugs at 30%. MRPs of 526 brands fell by up to 90%.
  • Decision-making. NPPA approved the 30% cap in principle at its 151st meeting on 8 October 2026. Its analysis found an average trade mark-up of about 170% on non-scheduled anti-cancer medicines, with some reaching 700%. The measure was projected to save patients about ₹2,500 crore annually.
  • Court hearing details.
    • The Court cited a cancer injection with a PTR of ₹11,000 that a hospital sold for ₹1.3 lakh, and a drip line bought for ₹15 and sold for ₹250.
    • It asked whether a uniform cap of about 16% over PTR could apply to all non-patented medicines.
    • NPPA's outstanding overcharging claims stood at ₹8,447.4 crore as of 31 March 2026.
    • At an earlier hearing the Centre argued that trade margins support supply in remote areas, and the Court said ensuring availability of price-controlled medicines is a government responsibility.
  • Later updates. On 28 October NPPA released revised MRPs for 543 anti-cancer brands, and updated the list to 1,085 medicines on 3 November 2026.
  • The Supreme Court's final order after the reserved judgment is not confirmed from the search results.

Mains dimensions

  • Right to health vs market logic. The Court's remark makes affordability of essential medicines a constitutional concern (Art. 21, Art. 47), against the Centre's argument that full control deters investment. The Bench's response suggests proportionate but firm regulation.
  • Regulatory credibility. "Totally defunct" and "why were you silent?" go to NPPA's enforcement record. The ₹8,447.4 crore outstanding overcharging claims (2b) indicates a recovery gap.
  • Design flaw in the two-tier system. The scheduled/non-scheduled divide leaves most medicines unregulated at launch, and the reach of price control depends on the NLEM. The Court asked on what basis "essential" is determined.
  • Supply-chain margin vs price control. Trade-margin rationalisation targets the gap between the price to retailer and the MRP. The Court cited a ₹15 drip line sold for ₹250 and an injection of PTR ₹11,000 sold for ₹1.3 lakh as evidence. The anti-cancer cap, based on the 2019 pilot (42 drugs, 526 brands, up to 90% cut), is the template.
  • Stakeholder tensions. Hospitals claim viability concerns, manufacturers fear shortages (the notification requires maintaining supply), and the Centre cites remote-area distribution. Judicial activism vs separation of powers: the Court nudged policy, and the Centre moved after court pressure.
  • Way forward.
  • Extend TMR in phases using expert committees.
  • Make Para 19 use predictable and rules-based.
  • Strengthen NPPA capacity and recovery of overcharged sums.
  • Improve price transparency and promote generics.

Possible Mains question

**GS3 / GS2, 15 marks:** "Examine the framework for regulating medicine prices in India. In light of recent judicial observations, evaluate the effectiveness of the National Pharmaceutical Pricing Authority and suggest reforms."

Related topics

  • Essential Commodities Act, 1955; National List of Essential Medicines; National Pharmaceutical Pricing Policy, 2012
  • Art. 21 (right to health; Paschim Banga Khet Mazdoor Samity, 1996), Art. 47
  • Drugs and Cosmetics Act, 1940; CDSCO; Jan Aushadhi; Ayushman Bharat
  • Out-of-pocket expenditure and health financing; price controls on stents and knee implants (examples of Para 19 use)
  • Judicial activism and policy domain; separation of powers

Topics: GS2Economy

How we write and check these notes →

All current affairs of 28 October 2026 → · UPSC Current Affairs